aTyr Pharma Announces First Quarter 2015 Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall St set for mixed open ahead of SK Hynix listing; Middle East in focus
- Oil heads for weekly gains as Middle East supply risks persist
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
aTyr Pharma (LIFE) Reports Q1 Loss of $9.39/Share
June 18, 2015 4:25 PM EDTaTyr Pharma (NASDAQ: LIFE) reported Q1 EPS of ($9.39), versus ($7.87) reported last year.
The Company successfully completed its initial public offering following the end of the quarter on May 12, 2015, with estimated net proceeds of $76.9 million. Total cash and investments are expected to be approximately $145 million as of June 30, 2015.
Proceeds raised during the first half of 2015 will be used to fund operations, including the ongoing Phase 1b/2 clinical trial of Resolaris, a first-in-class protein therapeutic in adult patients... More
